Clinical Trial Update: Study of Haemodialysis Patients Switching From Aranesp to Biosimilar

View source ↗

Summary

A completed clinical trial evaluating haemodialysis patients switching from Aranesp (darbepoetin alfa) to a biosimilar to assess outcomes after the switch.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)
• Darbepoetin alfa biosimilar (darbepoetin alfa)

Snippet

Sponsor: Amgen | Conditions: Anaemia | Status: COMPLETED